Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

A gas detection sheet has good gas detection sensitivity and excellent adhesion between a support and a porous coordination polymer, and an electrochemical element includes the gas detection sheet. The gas detection sheet includes a gas detection sheet support and a porous coordination polymer represented by general formula (1) supported on the support.

Fe.sub.x(Pyrazine)[Ni.sub.1-yM.sub.y(CN).sub.4](1)

(0.95x1.05, M=Pd, Pt, 0y<0.15)

By using the gas detection sheet wherein the gas detection sheet further contains a binder of 4% to 60% by mass based on the mass of the gas detection sheet, the gas detection sensitivity is excellent and the adhesion between the support and the porous coordination polymer is excellent.

The present invention provides a catalytic conversion-type sensor that detects a detection target gas by detecting a conversion gas produced through a reaction, the catalytic conversion-type sensor including: a gas flow path that allows the detection target gas to flow down; and a conversion portion that is connected to the gas flow path, the conversion portion including, on a side partitioned by a diffusion means that allows the detection target gas to naturally diffuse, a heated catalyst portion that produces a conversion gas by causing the detection target gas to come into contact with a heated catalyst and react with the heated catalyst, and a sensor element portion that is capable of detecting the conversion gas produced through the reaction.

A solution for extracting substantially pure RNA from a biological sample is disclosed. The solution for extracting RNA from a biological sample containing RNA and at least DNA comprises: (a) phenol in an amount of more than 50% by volume based on the total amount of the solution; (b) a polyol in an amount of 3 to 10% by volume based on the total amount of the solution; (c) a guanidinium salt at a concentration of 0.5 to 2.0 M based on the total amount of the solution; (d) a thiocyanate at a concentration of 0.1 to 0.5 M based on the total amount of the solution; and (e) a buffer for maintaining the pH of the solution at 4 to 6.

A main object of the present invention is to provide a novel acetylpolyamine detection agent that is easy to produce and use. This object is achieved by an acetylpolyamine detection agent comprising compound (A) having one or more polyether rings, wherein the polyether rings have one or more hydroxyl groups as substituents.

The present invention provides a method for forming a history of natural gas accumulation by using carbon isotopes by a pyrolysis experiment. The method includes: obtaining activation energy distribution and a frequency factor of light carbon methane; carrying out carbon isotope kinetics simulation of natural gas in a study area by using a spreadsheet function of Excel to obtain activation energy, a mass fraction and a frequency factor of heavy carbon methane; establishing a burial history and a thermal history of the study area based on geological data; and combining the activation energy distribution and frequency factor of the heavy carbon methane with the burial history and thermal history of the study area, and establishing an instantaneous curve, a cumulative curve and a stage cumulative curve of natural gas under geological conditions on a geologic time scale.

Disclosed are methods for determining the efficacy of a pharmacotherapy drug for kidney cancer using a blood test. The methods include the evaluation of the effect of a drug therapy for the treatment of kidney cancer by measuring the PARK7 level in a blood sample taken from a patient with kidney cancer who receives the drug therapy for the treatment of kidney cancer. An increased PARK7 level indicates that the drug therapy is not effective. Moreover, by using the blood PARK7 level as an indicator, the efficacy of a candidate substance for a therapeutic agent for kidney cancer can also be determined.

Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.

The disclosure discloses cerium sulfate chelated sulfur dioxide, a preparation method and a use thereof. The cerium sulfate chelated sulfur dioxide has a molecular formula of Ce[SO4][SO2].2H2O. It is a white crystal and the preparation method thereof may comprise the following steps: adding anhydrous cerium sulfate to dilute sulfuric acid with stirring for dissolvation; adding a solvent followed by refluxing at 45-50 C. for 2.0-2.5 h; heating the reaction product to remove the solvent, cooling to 20 C. or lower, and adding dilute sulfuric acid to allow precipitation of all crystals; cooling down the product followed by suction filtration, washing the obtained crystals by the solvent, so that crude cerium sulfate chelated sulfur dioxide can be obtained. The solubility of the cerium sulfate chelated sulfur dioxide of the disclosure has been significantly improved compared to the anhydrous cerium sulfate. The obtained solution is colorless and transparent, so that the cerium sulfate chelated sulfur dioxide can be used as a better titrant with wide application and supreme performance.

The disclosure discloses cerium sulfate chelated sulfur dioxide, a preparation method and a use thereof. The cerium sulfate chelated sulfur dioxide has a molecular formula of Ce[SO4][SO2].2H2O. It is a white crystal and the preparation method thereof may comprise the following steps: adding anhydrous cerium sulfate to dilute sulfuric acid with stirring for dissolvation; adding a solvent followed by refluxing at 45-50 C. for 2.0-2.5 h; heating the reaction product to remove the solvent, cooling to 20 C. or lower, and adding dilute sulfuric acid to allow precipitation of all crystals; cooling down the product followed by suction filtration, washing the obtained crystals by the solvent, so that crude cerium sulfate chelated sulfur dioxide can be obtained. The solubility of the cerium sulfate chelated sulfur dioxide of the disclosure has been significantly improved compared to the anhydrous cerium sulfate. The obtained solution is colorless and transparent, so that the cerium sulfate chelated sulfur dioxide can be used as a better titrant with wide application and supreme performance.